Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2001
Business Overview: The Company develops, manufactures, and markets oral specimen collection devices, oral fluid assays, and diagnostic products. Operations are conducted primarily in the United States and Europe.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenue | $7,404,024 | $6,619,373 |
| Net Loss | $(996,759) | $(833,748) |
| Operating Loss | $(1,232,152) | $(892,919) |
| Gross Margin | 64% | 62% |
| Cash and Cash Equivalents | $6,030,738 | $8,358,448 |
| Short-term Investments | $10,638,537 | $14,956,779 |
| Total Debt (Current + Long-term) | $5,494,634 | $5,769,236 |
| Working Capital | $20,152,734 | $21,494,989 |
| Net Cash Used in Operating Activities | $(2,473,120) | $(1,605,280) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12% year-over-year, driven by a 29% increase in oral specimen collection device sales and a 289% surge in licensing and product development revenue (attributed to a research agreement with Drager).
- Product Mix Shifts: Sales of the discontinued Serum Western Blot product declined 46%. Conversely, the new OraQuick HIV test generated $234,000 in revenue following its market introduction in sub-Saharan Africa.
- Expense Increases: Operating expenses rose 15% due to a 26% increase in R&D (clinical trials for OraQuick and UPlink) and a 33% increase in sales and marketing. A one-time $450,000 restructuring charge was recorded for manufacturing realignment.
- Profitability: Net loss widened by 20% to approximately $997,000. Excluding the restructuring charge, the adjusted net loss would have been approximately $547,000.
- Liquidity: Cash and short-term investments decreased by $3.4 million to $16.7 million, primarily due to operating losses, increased receivables/inventory, and capital expenditures for facility upgrades.
Guidance, Outlook, and Risks
- Manufacturing Restructuring: The Company eliminated OraQuick manufacturing in Beaverton, Oregon, and commenced assembly in Thailand to expand capacity. Management expects no financial impact from this restructuring in 2001 and anticipates gross margin improvements in Q2 2001.
- Outlook: R&D expenses are expected to increase throughout 2001 due to ongoing clinical trials. The Company believes its current cash position and credit facilities are sufficient to fund foreseeable needs.
- Customer Concentration Risk: One customer accounted for 24% of total revenues in Q1 2001. The loss of this customer would have a material adverse effect.
- Regulatory and Market Risks: Future performance depends on obtaining regulatory approvals, market acceptance of oral fluid testing, and the ability to commercialize new products like OraQuick and UPlink.
- Accounting Change: The Company changed its independent public accountants from PricewaterhouseCoopers LLP to Arthur Andersen LLP.
Investor Verification Checklist
- Verify the timeline and cost implications of the manufacturing transition from Oregon to Thailand.
- Confirm the status of regulatory approvals for the OraQuick HIV-1/2 rapid test and UPlink system.
- Assess the stability of the top customer representing 24% of revenue.
- Monitor the burn rate of cash given the continued net losses and increased R&D spend.
- Review the renewal status of the $1.0 million working capital and equipment lines of credit expiring June 30, 2001.